查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1803001

全球組織分離市場：2032 年預測 - 按產品、組織類型、技術、應用、最終用戶和地區進行分析

Tissue Dissociation Market Forecasts to 2032 - Global Analysis By Product, Tissue Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球組織解離市場預計在 2025 年達到 3.607 億美元，到 2032 年將達到 7.301 億美元，預測期內的複合年成長率為 10.6%。

組織解離是將複雜的生物組織分解成單一可存活細胞的過程，用於治療方法和治療應用。該技術對於單細胞分析、細胞培養和流式細胞技術至關重要，使科學家能夠精確地研究細胞行為和多樣性。處理方法包括機械破碎、酵素消化和化學處理，每種方法都旨在維持細胞的完整性和功能性。將細胞從其原生組織環境中分離出來，使研究人員能夠更深入地了解疾病機制、藥物反應和再生療法，使組織解離成為現代生物醫學的基本步驟。

根據世界衛生組織（WHO）的數據，預計到2030年，全球慢性病負擔將佔所有死亡人數的70%。

細胞治療方法的興起

由於對高品質單細胞懸浮液的需求不斷成長，細胞治療方法的蓬勃發展正推動組織分離市場的強勁成長。隨著再生醫學、免疫療法和幹細胞應用的不斷擴展，精準高效的分離技術對於下游分析和療效至關重要。這一勢頭正在推動酶解和機械分離工具的創新，加速研究工作流程並提高臨床可擴展性。最終，這一趨勢正在將組織處理轉化為下一代生物醫學突破的關鍵推動因素。

酵素的變異性和批次不一致

酵素的變異性和批次不一致嚴重阻礙了組織分離市場的發展，因為它們會影響可重複性、可擴展性和下游資料的完整性。酵素活性不一致會導致細胞產量和活力難以預測，進而損害研究結果和臨床應用的可靠性。這種變異性會增加驗證成本，延遲產品開發，並阻礙分離試劑套件在法規環境中的普及。最終，它限制了再生醫學、單細胞分析和生物加工領域的市場成長和創新。

單細胞分析的進展

單細胞分析技術的進步正在徹底改變組織分離市場，推動對精準度、擴充性和自動化的需求。微流體和酵素技術的改進使得高產量活細胞分離成為可能，這對於細胞治療和個人化醫療等下游應用至關重要。與人工智慧和自動化平台的整合可以加速工作流程，減少差異性並提高可重複性。這些技術創新正在推動整個生物製藥和研究領域的成長，尤其是在亞太地區，而生物技術領域的支持性政策和投資正在加速市場擴張。

尖端技術成本高昂

先進組織分離技術成本高昂，限制了小型研究機構和新興生物技術公司的可近性，阻礙了市場成長。這些成本導致營運預算膨脹，限制了其廣泛應用，並延緩了細胞治療方法和診斷領域的創新。此外，成本壁壘阻礙了新興市場的投資，加劇了全球生物醫學研究能力的差距，並降低了組織分離解決方案的整體擴充性和商業性可行性，從而限制了市場擴張。

COVID-19的影響

新冠疫情加速了組織分離市場的需求，這主要得益於疫苗和治療方法研發的迫切性。儘管初期實驗室工作受到干擾，但遠端研究和分散式工作流程仍保持了強勁成長動能。組織分離酶和儀器對於單株抗體生產和細胞分析中細胞分離至關重要。生物醫學研發的蓬勃發展，尤其是在再生醫學和免疫療法領域，為疫情後市場強勁成長奠定了基礎。

再生醫學預計將成為預測期內最大的細分市場

受先進酶解和機械解離工具需求的推動，再生醫學領域預計將在預測期內佔據最大的市場佔有率佔有率。隨著細胞療法、幹細胞研究和類器官開發的蓬勃發展，精準的組織處理至關重要。這一趨勢正在推動解離試劑和儀器的創新，從而提高細胞產量和活力。隨著再生醫學擴展到腫瘤學、骨科和神經內科，組織解離技術將成為實現下一代治療突破的基礎，再生醫學市場正呈現持續成長動能。

預計動物組織部分將在預測期內實現最高的複合年成長率

動物組織細分市場預計將在預測期內呈現最高成長率，因為它在生產用於研究和治療應用的高品質單細胞懸浮液方面發揮關鍵作用。其在酵素解離技術中的應用能夠精確分解細胞外基質，進而提高細胞活力和產量。這在腫瘤學、免疫學和再生醫學等領域尤其重要。個人化治療和先進的細胞檢測方法的需求日益成長，使得基於動物組織的分離工具變得至關重要，從而刺激了市場擴張和技術創新。

佔比最大的地區：

預計亞太地區將在預測期內佔據最大的市場佔有率。受細胞療法、癌症研究和精準醫療投資不斷增加的推動，該地區正見證酶解和機械解離技術的快速應用。這些技術創新實現了高效的單細胞分離，加速了幹細胞應用和藥物研發的突破。隨著醫療基礎設施的不斷完善和生物技術政策的支持，亞太地區正在成為全球組織解離技術的中心，促進科學進步和治療創新。

複合年成長率最高的地區：

預計北美在預測期內的複合年成長率最高。對單細胞分析和精準診斷的需求正在推動該地區酶解和機械解離技術的創新。這一勢頭正在支持腫瘤學、神經科學和幹細胞治療領域的突破，從而提高研究效率和臨床療效。生物技術公司與學術機構之間的策略聯盟正在進一步加速技術的應用，使北美成為推動以細胞為基礎的應用和個人化醫療解決方案的全球領導者。

免費客製化服務

此報告的訂閱者可以從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 簡介

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 主要研究資料
    • 二手研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 市場機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 企業之間的競爭

5. 全球組織分離市場（按產品）

  • 酵素解離產物
  • 機械解離產物
  • 化學解離產物
  • 細胞過濾器
  • 移液管和流量控制裝置

6. 全球組織分離市場（依組織類型）

  • 人體組織
  • 固態組織
  • 液體組織
  • 動物組織

7. 全球組織分離市場（依技術）

  • 手動組織解剖
  • 自動組織分離

8. 全球組織分離市場（按應用）

  • 癌症研究
  • 幹細胞研究
  • 細胞療法
  • 再生醫學
  • 基因組學和蛋白​​質組學
  • 其他用途

9. 全球組織分離市場（依最終用戶）

  • 醫院和診斷實驗室
  • 學術研究機構
  • 製藥和生物技術公司
  • 合約研究業務（CRO）
  • 其他最終用戶

第10章。全球組織解離市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併與收購（M&A）
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Thermo Fisher Scientific Inc.
  • Miltenyi Biotec
  • Worthington Biochemical Corporation
  • Roche Diagnostics
  • Sigma-Aldrich
  • BD Biosciences
  • STEMCELL Technologies Inc.
  • Corning Incorporated
  • Takara Bio Inc.
  • Bio-Rad Laboratories, Inc.
  • PromoCell GmbH
  • CellSystems Biotechnologie Vertrieb GmbH
  • PanReac AppliChem GmbH
  • Enzymatics Inc.
  • Creative Bioarray
  • Cell Biolabs, Inc.
  • Biovision, Inc.
  • Cyagen Biosciences Inc.
  • Genlantis
  • HiMedia Laboratories Pvt. Ltd.
Product Code: SMRC30527

According to Stratistics MRC, the Global Tissue Dissociation Market is accounted for $360.7 million in 2025 and is expected to reach $730.1 million by 2032 growing at a CAGR of 10.6% during the forecast period. Tissue dissociation is the process of breaking down complex biological tissues into individual, viable cells for research or therapeutic applications. This technique is essential for single-cell analysis, cell culture, and flow cytometry, allowing scientists to study cellular behavior and diversity with precision. Methods include mechanical disruption, enzymatic digestion, and chemical treatments, each tailored to preserve cell integrity and functionality. By isolating cells from their native tissue environment, researchers gain deeper insights into disease mechanisms, drug responses, and regenerative therapies, making tissue dissociation a foundational step in modern biomedical science.

According to the World Health Organization (WHO), the global burden of chronic diseases is projected to reach 70% of all deaths by 2030.

Market Dynamics:

Driver:

Surge in Cell-Based Therapies

The surge in cell-based therapies is catalyzing robust growth in the tissue dissociation market, driven by rising demand for high-quality single-cell suspensions. As regenerative medicine, immunotherapy, and stem cell applications expand, precise and efficient dissociation techniques become critical for downstream analysis and therapeutic efficacy. This momentum is fostering innovation in enzymatic and mechanical dissociation tools, accelerating research workflows and clinical scalability. Ultimately, the trend is transforming tissue processing into a pivotal enabler of next-generation biomedical breakthroughs.

Restraint:

Enzyme Variability and Batch Inconsistency

Enzyme variability and batch inconsistency significantly hinder the tissue dissociation market by compromising reproducibility, scalability, and downstream data integrity. Inconsistent enzymatic activity leads to unpredictable cell yields and viability, undermining confidence in research outcomes and clinical applications. This variability increases validation costs, delays product development, and deters adoption of dissociation kits in regulated environments. Ultimately, it restricts market growth and innovation across regenerative medicine, single-cell analysis, and bioprocessing sectors.

Opportunity:

Advancements in Single-Cell Analysis

Advancements in single-cell analysis are revolutionizing the tissue dissociation market by driving demand for precision, scalability, and automation. Enhanced microfluidic and enzymatic techniques now enable high-yield, viable cell isolation, crucial for downstream applications like cell therapy and personalized medicine. Integration with AI and automated platforms accelerates workflows, reduces variability, and boosts reproducibility. These innovations are catalyzing growth across biopharma and research sectors, especially in Asia-Pacific, where supportive policies and biotech investments are amplifying market expansion.

Threat:

High Costs of Advanced Technologies

The high costs of advanced tissue dissociation technologies significantly hinder market growth by limiting accessibility for smaller research institutions and emerging biotech firms. These expenses inflate operational budgets; restrict widespread adoption, and slow innovation in cell-based therapies and diagnostics. Additionally, cost barriers deter investment in developing regions, exacerbating global disparities in biomedical research capabilities and reducing the overall scalability and commercial viability of tissue dissociation solutions, thus it limits market expansion.

Covid-19 Impact

The Covid-19 pandemic accelerated demand in the tissue dissociation market, driven by urgent vaccine and therapeutic development. Despite initial lab disruptions, remote research and decentralized workflows sustained momentum. Tissue dissociation enzymes and instruments became vital for isolating cells used in monoclonal antibody production and cell-based assays. This surge in biomedical R&D, especially in regenerative medicine and immunotherapy, positioned the market for robust post-pandemic growth.

The regenerative medicine segment is expected to be the largest during the forecast period

The regenerative medicine segment is expected to account for the largest market share during the forecast period, due to demand for advanced enzymatic and mechanical dissociation tools. As cell-based therapies, stem cell research, and organoid development surge, precise tissue processing becomes critical. This trend fosters innovation in dissociation reagents and instruments, enhancing cell yield and viability. With regenerative medicine expanding across oncology, orthopedics, and neurology, the market is witnessing sustained momentum, positioning tissue dissociation as a foundational enabler of next-gen therapeutic breakthroughs.

The animal tissue segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the animal tissue segment is predicted to witness the highest growth rate, due to its critical role in producing high-quality single-cell suspensions for research and therapeutic applications. Its use in enzymatic dissociation techniques enables precise breakdown of extracellular matrices, enhancing cell viability and yield. This is especially vital for fields like oncology, immunology, and regenerative medicine. As demand for personalized therapies and advanced cell-based assays rises, animal tissue-based dissociation tools are becoming indispensable, fueling market expansion and innovation.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising investments in cell-based therapies, cancer research, and precision medicine, the region is witnessing rapid adoption of enzymatic and mechanical dissociation technologies. These innovations enable efficient single-cell isolation, accelerating breakthroughs in stem cell applications and drug discovery. With growing healthcare infrastructure and supportive biotech policies, Asia Pacific is emerging as a global hub for tissue dissociation, fostering scientific advancement and therapeutic innovation.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to demand for single-cell analysis and precision diagnostics, the region fosters innovation in enzymatic and mechanical dissociation technologies. This momentum supports breakthroughs in oncology, neuroscience, and stem cell therapies, enhancing research efficiency and clinical outcomes. Strategic collaborations between biotech firms and academic institutions further accelerate adoption, positioning North America as a global leader in advancing cell-based applications and personalized healthcare solutions.

Key players in the market

Some of the key players profiled in the Tissue Dissociation Market include Thermo Fisher Scientific Inc., Miltenyi Biotec, Worthington Biochemical Corporation, Roche Diagnostics, Sigma-Aldrich, BD Biosciences, STEMCELL Technologies Inc., Corning Incorporated, Takara Bio Inc., Bio-Rad Laboratories, Inc., PromoCell GmbH, CellSystems Biotechnologie Vertrieb GmbH, PanReac AppliChem GmbH, Enzymatics Inc., Creative Bioarray, Cell Biolabs, Inc., Biovision, Inc., Cyagen Biosciences Inc., Genlantis and HiMedia Laboratories Pvt. Ltd.

Key Developments:

In July 2025, Thermo Fisher deepens its bond with Sanofi by acquiring a sterile fill-finish site in New Jersey. Over 200 local employees will join the fold, bolstering U.S. drug manufacturing capacity and honoring a tradition of domestic, dependable production. The move strengthens domestic manufacturing and is expected to close in H2 2025.

In July 2025, Takara Bio Europe and MACHEREY-NAGEL have joined forces in a bold distribution pact, delivering MN's precise RNA, DNA, and protein purification tools across ten European nations-melding upstream extraction with downstream PCR and NGS workflows, empowering scientists with seamless reliability.

In March 2025, Roche and Zealand Pharma unite, weaving a promising alliance to co-develop petrelintide-an amylin analog-for standalone use and in fusion with Roche's CT-388. This bold fusion may reshape obesity treatment, confronting its vast complexity and unmet needs with refined innovation.

Products Covered:

  • Enzymatic Dissociation Products
  • Mechanical Dissociation Products
  • Chemical Dissociation Products
  • Cell Strainers
  • Pipettes and Regulated Flow Devices

Tissue Types Covered:

  • Human Tissue
  • Solid Tissue
  • Liquid Tissue
  • Animal Tissue

Technologies Covered:

  • Manual Tissue Dissociation
  • Automated Tissue Dissociation

Applications Covered:

  • Cancer Research
  • Stem Cell Research
  • Cell Therapy
  • Regenerative Medicine
  • Genomics & Proteomics
  • Other Applications

End Users Covered:

  • Hospitals & Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Tissue Dissociation Market, By Product

  • 5.1 Introduction
  • 5.2 Enzymatic Dissociation Products
  • 5.3 Mechanical Dissociation Products
  • 5.4 Chemical Dissociation Products
  • 5.5 Cell Strainers
  • 5.6 Pipettes and Regulated Flow Devices

6 Global Tissue Dissociation Market, By Tissue Type

  • 6.1 Introduction
  • 6.2 Human Tissue
  • 6.3 Solid Tissue
  • 6.4 Liquid Tissue
  • 6.5 Animal Tissue

7 Global Tissue Dissociation Market, By Technology

  • 7.1 Introduction
  • 7.2 Manual Tissue Dissociation
  • 7.3 Automated Tissue Dissociation

8 Global Tissue Dissociation Market, By Application

  • 8.1 Introduction
  • 8.2 Cancer Research
  • 8.3 Stem Cell Research
  • 8.4 Cell Therapy
  • 8.5 Regenerative Medicine
  • 8.6 Genomics & Proteomics
  • 8.7 Other Applications

9 Global Tissue Dissociation Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Diagnostic Laboratories
  • 9.3 Academic & Research Institutes
  • 9.4 Pharmaceutical & Biotechnology Companies
  • 9.5 Contract Research Organizations (CROs)
  • 9.6 Other End Users

10 Global Tissue Dissociation Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 Miltenyi Biotec
  • 12.3 Worthington Biochemical Corporation
  • 12.4 Roche Diagnostics
  • 12.5 Sigma-Aldrich
  • 12.6 BD Biosciences
  • 12.7 STEMCELL Technologies Inc.
  • 12.8 Corning Incorporated
  • 12.9 Takara Bio Inc.
  • 12.10 Bio-Rad Laboratories, Inc.
  • 12.11 PromoCell GmbH
  • 12.12 CellSystems Biotechnologie Vertrieb GmbH
  • 12.13 PanReac AppliChem GmbH
  • 12.14 Enzymatics Inc.
  • 12.15 Creative Bioarray
  • 12.16 Cell Biolabs, Inc.
  • 12.17 Biovision, Inc.
  • 12.18 Cyagen Biosciences Inc.
  • 12.19 Genlantis
  • 12.20 HiMedia Laboratories Pvt. Ltd.

List of Tables

  • Table 1 Global Tissue Dissociation Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Tissue Dissociation Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Tissue Dissociation Market Outlook, By Enzymatic Dissociation Products (2024-2032) ($MN)
  • Table 4 Global Tissue Dissociation Market Outlook, By Mechanical Dissociation Products (2024-2032) ($MN)
  • Table 5 Global Tissue Dissociation Market Outlook, By Chemical Dissociation Products (2024-2032) ($MN)
  • Table 6 Global Tissue Dissociation Market Outlook, By Cell Strainers (2024-2032) ($MN)
  • Table 7 Global Tissue Dissociation Market Outlook, By Pipettes and Regulated Flow Devices (2024-2032) ($MN)
  • Table 8 Global Tissue Dissociation Market Outlook, By Tissue Type (2024-2032) ($MN)
  • Table 9 Global Tissue Dissociation Market Outlook, By Human Tissue (2024-2032) ($MN)
  • Table 10 Global Tissue Dissociation Market Outlook, By Solid Tissue (2024-2032) ($MN)
  • Table 11 Global Tissue Dissociation Market Outlook, By Liquid Tissue (2024-2032) ($MN)
  • Table 12 Global Tissue Dissociation Market Outlook, By Animal Tissue (2024-2032) ($MN)
  • Table 13 Global Tissue Dissociation Market Outlook, By Technology (2024-2032) ($MN)
  • Table 14 Global Tissue Dissociation Market Outlook, By Manual Tissue Dissociation (2024-2032) ($MN)
  • Table 15 Global Tissue Dissociation Market Outlook, By Automated Tissue Dissociation (2024-2032) ($MN)
  • Table 16 Global Tissue Dissociation Market Outlook, By Application (2024-2032) ($MN)
  • Table 17 Global Tissue Dissociation Market Outlook, By Cancer Research (2024-2032) ($MN)
  • Table 18 Global Tissue Dissociation Market Outlook, By Stem Cell Research (2024-2032) ($MN)
  • Table 19 Global Tissue Dissociation Market Outlook, By Cell Therapy (2024-2032) ($MN)
  • Table 20 Global Tissue Dissociation Market Outlook, By Regenerative Medicine (2024-2032) ($MN)
  • Table 21 Global Tissue Dissociation Market Outlook, By Genomics & Proteomics (2024-2032) ($MN)
  • Table 22 Global Tissue Dissociation Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 23 Global Tissue Dissociation Market Outlook, By End User (2024-2032) ($MN)
  • Table 24 Global Tissue Dissociation Market Outlook, By Hospitals & Diagnostic Laboratories (2024-2032) ($MN)
  • Table 25 Global Tissue Dissociation Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 26 Global Tissue Dissociation Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 27 Global Tissue Dissociation Market Outlook, By Contract Research Organizations (CROs) (2024-2032) ($MN)
  • Table 28 Global Tissue Dissociation Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.